Mark Adams

Two Bear Capital thesis

Abilita Therapeutics Abilita Therapeutics enables discovery of novel therapeutics for previously undruggable membrane protein targets. Abilita Therapeutics enables discovery of novel therapeutics for previously undruggable membrane protein targets. About the company Abilita Therapeutics on LinkedIn Abilita Therapeutics website Abilita Therapeutics is a biotech company specializing in discovering and developing therapies for the most challenging membrane proteins, including GPCRs, ion channels and transporters. Despite their high significance, hundreds of such drug targets remain untapped. Abil

Sector and stage focus

• Seed: Pharmaceuticals, Cloud Infrastructure, Digital Health, Drug Delivery, Health IT, Therapeutics, AI, Cybersecurity, Enterprise Infrastructure, BioTech
• Series A: Health IT, Cloud Infrastructure, Digital Health, BioTech, AI, Pharmaceuticals, Therapeutics, Cybersecurity, Drug Delivery, Enterprise Infrastructure
• general: New York City, Investors who invested in female founders, Investors who were founders, Investors who invested in diverse founders

Is Mark Adams a fit for your round?

Upload your pitch deck and see whether Mark Adams appears in your top 20 matches.